Related Experiment Videos
Herpetic esophagitis following bendamustine-containing regimen.
Hiromichi Yamane1, Yasumasa Monobe2, Tomohiro Tanikawa3
1Department of General Internal Medicine 4, Kawasaki Medical School, Kita-ku, Okayama, Japan.
Therapeutics and Clinical Risk Management
|June 23, 2016
Summary
Herpetic esophagitis is a rare adverse event following bendamustine and rituximab (B-R) chemotherapy for non-Hodgkin's lymphoma. This complication can cause significant gastrointestinal discomfort, requiring medical awareness.
Area of Science:
- Oncology
- Gastroenterology
- Infectious Diseases
Background:
- A 76-year-old woman with a history of non-Hodgkin's lymphoma underwent salvage chemotherapy.
- Treatment involved bendamustine and rituximab (B-R), leading to prolonged bone marrow suppression exceeding three months.
Observation:
- The patient presented with anorexia and subsequent esophagogastroscopy revealed multiple white protrusions in the mid-esophagus.
- These esophageal lesions were diagnosed as herpetic esophagitis.
Findings:
- This case represents the first documented instance of herpetic esophagitis as an adverse event associated with the bendamustine and rituximab (B-R) regimen.
- The patient's presentation highlights a novel complication of this specific chemotherapy combination.
Implications:
- Herpetic esophagitis can manifest as a serious gastrointestinal complication following B-R chemotherapy.
- Awareness among healthcare providers is crucial for timely diagnosis and management of this adverse event in lymphoma patients.
Related Concept Videos
01:21Barrett Esophagus-II: Clinical Manifestations and Management
1.4K
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
1.4K
01:30Esophageal Strictures-I: Introduction
1.1K
Esophageal strictures involve abnormal narrowing or tightening of the esophagus. They vary in length and severity, ranging from mild constriction to complete obstruction, and are classified as benign (noncancerous) or malignant (cancerous).
Etiology
The primary cause of esophageal strictures is long-standing gastroesophageal reflux disease (GERD), accounting for about 70 to 80% of adult cases. Chronic acid reflux can lead to injury and scarring of the esophageal lining, culminating in...
Etiology
The primary cause of esophageal strictures is long-standing gastroesophageal reflux disease (GERD), accounting for about 70 to 80% of adult cases. Chronic acid reflux can lead to injury and scarring of the esophageal lining, culminating in...
1.1K
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
1.1K
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.1K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
777
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
777
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.9K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.9K
01:14Myocarditis III: Medical Management
309
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
309